Online citations, reference lists, and bibliographies.
← Back to Search

Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy In Advanced Malignant Pleural Mesothelioma

Xu-quan Jing, Lei Zhou, X. Sun, J. Yu, X. Meng
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AbstractMalignant pleural mesothelioma (MPM) is a lethal disease with poor prognosis. The combination of cisplatin and pemetrexed has been confirmed as the standard of care for nonoperable MPM. Data have shown that the adoption of pemetrexed maintenance therapy (PMT) following first-line treatment appears extremely promising.We describe a 57-year-old man diagnosed as advanced MPM. We treated this patient with PMT after first-line cisplatin-based bevacizumab-containing chemotherapy and residual tumor disappeared after 6 course of PMT. A perfect response and a long progression-free survival (PFS) were reached with tumor mass disappearing and 14 months duration of PFS.This case suggests that adding bevacizumab to standard first-line chemotherapy is feasible and that PMT could be promising and useful for treating advanced MPM. We further entail a review of the literature on the first-line treatment, continuation maintenance therapy, switch maintenance therapy, and second-line treatment of patients with advanced MPM.
This paper references
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.1016/j.ctrv.2012.12.005
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1016/j.ctrv.2011.01.001
Advances in the biology of malignant pleural mesothelioma.
P. Zucali (2011)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
Bevacizumab 15 mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial
G Zalcman (2015)
10.1200/JCO.2012.47.9626
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J. Patel (2013)
10.1200/JCO.2008.20.8181
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
J. Patel (2009)
April 2016 Pemetrexed Maintenance Therapy of MPM Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal
Randomized double-blind placebocontrolled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer
SM Lee (2009)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1038/nrd1381
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N. Ferrara (2004)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1200/JCO.2000.18.14.2710
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
S. Baidas (2000)
10.1200/JCO.2009.21.9733
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
S. Lee (2009)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1093/jnci/djp200
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Siow Ming Lee (2009)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1093/annonc/mdu098
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
F. Barlesi (2014)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1093/OXFORDJOURNALS.ANNONC.A059253
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
A. Planting (1995)
10.1016/S0169-5002(98)00072-5
Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
A. Purohit (1998)
10.1097/JTO.0b013e3181d2f008
Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma
A. Yasumitsu (2010)
md-journal.com Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved
Www
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1016/j.ctrv.2014.10.007
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
10.1007/978-3-642-10862-4_2
Epidemiology of mesothelioma and historical background.
J. Craighead (2011)
10.1016/S1470-2045(12)70063-3
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
L. Paz-Ares (2012)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1186/1745-6673-3-34
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar